-
公开(公告)号：US07723312B2
公开(公告)日：2010-05-25
申请号：US11262388
申请日：2005-10-28
CPC分类号： C12N15/113 , A61K31/337 , A61K31/7068 , A61K31/7088 , A61K31/7125 , A61K31/713 , A61K48/005 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2320/30 , C12N2320/31
摘要： Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.
-
公开(公告)号：US07847091B2
公开(公告)日：2010-12-07
申请号：US12416305
申请日：2009-04-01
CPC分类号： C12N15/113 , A61K31/337 , A61K31/7068 , A61K31/7088 , A61K31/7125 , A61K31/713 , A61K48/005 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2320/30 , C12N2320/31
摘要： Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.
摘要翻译： 靶向体内热休克蛋白（hsp）27的治疗剂用于为患有前列腺癌和过表达hsp27的其他癌症的个体，特别是人类个体提供治疗。 将治疗剂，例如具有hsp27mRNA的序列特异性的反义寡核苷酸或RNAi核苷酸抑制剂（例如人hsp27 mRNA）施用于患有前列腺癌或表达治疗有效量的高水平hsp27的一些其它癌症的个体 。 治疗剂适当地配制成包含药学上可接受的载体并以剂量单位形式包装的药物组合物。 优选的剂量单位形式是可注射剂量单位形式。
-
公开(公告)号：US20090221678A1
公开(公告)日：2009-09-03
申请号：US12416305
申请日：2009-04-01
IPC分类号： A61K31/7088
CPC分类号： C12N15/113 , A61K31/337 , A61K31/7068 , A61K31/7088 , A61K31/7125 , A61K31/713 , A61K48/005 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2320/30 , C12N2320/31
摘要： Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.
摘要翻译： 靶向体内热休克蛋白（hsp）27的治疗剂用于为患有前列腺癌和过表达hsp27的其他癌症的个体，特别是人类个体提供治疗。 将治疗剂，例如具有hsp27mRNA的序列特异性的反义寡核苷酸或RNAi核苷酸抑制剂（例如人hsp27 mRNA）施用于患有前列腺癌或表达治疗有效量的高水平hsp27的一些其它癌症的个体 。 治疗剂适当地配制成包含药学上可接受的载体并以剂量单位形式包装的药物组合物。 优选的剂量单位形式是可注射剂量单位形式。
-
公开(公告)号：US07101991B2
公开(公告)日：2006-09-05
申请号：US10605498
申请日：2003-10-02
CPC分类号： C12N15/113 , A61K31/337 , A61K31/7068 , A61K31/7088 , A61K31/7125 , A61K31/713 , A61K48/005 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2320/30 , C12N2320/31
摘要： Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.
-
公开(公告)号：US20090292008A1
公开(公告)日：2009-11-26
申请号：US12490018
申请日：2009-06-23
IPC分类号： A61K31/7088 , A61P35/00
CPC分类号： A61K31/7088
摘要： Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.
摘要翻译： 靶向体内热休克蛋白（hsp）27的治疗剂用于为患有前列腺癌和过表达hsp27的其他癌症的个体，特别是人类个体提供治疗。 向治疗有效量的患有前列腺癌或一些表达升高水平的hsp27的其他癌症的个体施用治疗剂，例如具有hsp27 mRNA的序列特异性的反义寡核苷酸或RNAi核苷酸抑制剂，例如人hsp27 mRNA。 治疗剂适当地配制成包含药学上可接受的载体并以剂量单位形式包装的药物组合物。 优选的剂量单位形式是可注射剂量单位形式。
-
公开(公告)号：US08722872B2
公开(公告)日：2014-05-13
申请号：US12490018
申请日：2009-06-23
CPC分类号： A61K31/7088
摘要： Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.
摘要翻译： 靶向体内热休克蛋白（hsp）27的治疗剂用于为患有前列腺癌和过表达hsp27的其他癌症的个体，特别是人类个体提供治疗。 向治疗有效量的患有前列腺癌或一些表达升高水平的hsp27的其他癌症的个体施用治疗剂，例如具有hsp27 mRNA的序列特异性的反义寡核苷酸或RNAi核苷酸抑制剂，例如人hsp27 mRNA。 治疗剂适当地配制成包含药学上可接受的载体并以剂量单位形式包装的药物组合物。 优选的剂量单位形式是可注射剂量单位形式。
-
公开(公告)号：US20060276424A1
公开(公告)日：2006-12-07
申请号：US11422481
申请日：2006-06-06
申请人： Martin Gleave , Palma Rocchi , Maxim Signaevsky , Eliana Beraldi
发明人： Martin Gleave , Palma Rocchi , Maxim Signaevsky , Eliana Beraldi
IPC分类号： A61K48/00
CPC分类号： C12N15/113 , A61K31/337 , A61K31/7068 , A61K31/7088 , A61K31/7125 , A61K31/713 , A61K48/005 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2320/30 , C12N2320/31
摘要： Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.
-
公开(公告)号：US20060040886A1
公开(公告)日：2006-02-23
申请号：US11262388
申请日：2005-10-28
申请人： Martin Gleave , Palma Rocchi , Maxim Signaevsky , Eliana Beraldi
发明人： Martin Gleave , Palma Rocchi , Maxim Signaevsky , Eliana Beraldi
IPC分类号： A61K48/00
CPC分类号： C12N15/113 , A61K31/337 , A61K31/7068 , A61K31/7088 , A61K31/7125 , A61K31/713 , A61K48/005 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2320/30 , C12N2320/31
摘要： Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.
-
公开(公告)号：US08772470B1
公开(公告)日：2014-07-08
申请号：US11948195
申请日：2007-11-30
申请人： Martin Gleave , Palma Rocchi , Maxim Signaevsky , Eliana Beraldi
发明人： Martin Gleave , Palma Rocchi , Maxim Signaevsky , Eliana Beraldi
CPC分类号： C12N15/113 , A61K31/337 , A61K31/7068 , A61K31/7088 , A61K31/7125 , A61K31/713 , A61K48/005 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2320/30 , C12N2320/31
摘要： Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.
摘要翻译： 靶向体内热休克蛋白（hsp）27的治疗剂用于为患有前列腺癌和过表达hsp27的其他癌症的个体，特别是人类个体提供治疗。 将治疗剂，例如具有hsp27mRNA的序列特异性的反义寡核苷酸或RNAi核苷酸抑制剂（例如人hsp27 mRNA）施用于患有前列腺癌或表达治疗有效量的高水平hsp27的一些其它癌症的个体 。 治疗剂适当地配制成包含药学上可接受的载体并以剂量单位形式包装的药物组合物。 优选的剂量单位形式是可注射剂量单位形式。
-
公开(公告)号：US08492534B1
公开(公告)日：2013-07-23
申请号：US11948195
申请日：2007-11-30
申请人： Martin Gleave , Palma Rocchi , Maxim Signaevsky , Eliana Beraldi
发明人： Martin Gleave , Palma Rocchi , Maxim Signaevsky , Eliana Beraldi
摘要： Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.
-
-
-
-
-
-
-
-
-
搜索结果
26 条记录 (耗时 0.019 秒)
